| 发明名称 |
Therapeutic IL-13 Polypeptides |
| 摘要 |
Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13Rα2, relative to the native human IL-13 protein; (b) altered affinity for IL-13Rα1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4Rα relative to the native human IL-13 protein. |
| 申请公布号 |
US2017066809(A1) |
申请公布日期 |
2017.03.09 |
| 申请号 |
US201615353273 |
申请日期 |
2016.11.16 |
| 申请人 |
The Board of Trustees of the Leland Stanford Junior University |
发明人 |
Garcia Kenan Christopher;Gonzalez Ignacio Moraga |
| 分类号 |
C07K14/54;C07K16/00 |
主分类号 |
C07K14/54 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A polypeptide comprising:
a modified interleukin 13 (IL-13) engineered to have increased affinity for interleukin 13 receptor α2 (IL-13Rα2), relative to native human IL 13 protein; (b) and decreased affinity for interleukin 13 receptor α1 (IL-13Rα1) relative to native human IL 13 protein; wherein the modified IL-13 polypeptide comprises amino acid changes relative to wild type IL-13 at positions L10, R86, D87, T88 and R108. |
| 地址 |
Stanford CA US |
